Quanterix Entered into a Collaboration with Eli Lilly to Develop Plasma-Based Biomarkers for Alzheimer’s Disease
Shots:
- Quanterix to get a non-exclusive license globally to Lilly’s P-tau217 Ab technology for research use including products, services & in vitro diagnostic applications. Lilly will be responsible to fund $11M of development with the Quanterix Accelerator group in 2022
- The collaboration will combine Lilly’s P-tau217 and Quanterix’ Simoa technologies to develop plasma-based biomarkers & provide assess to treatment for patients with AD
- In P-II (TRAILBLAZER-ALZ) study, the therapy showed a reduction in plasma levels of phosphorylated tau protein after treatment with donanemab for AD. The companies also collaborated for future projects focused on the development of Simoa immunoassays
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.